Skip to content

BridgeBio Pharma BBIO Debt-to-equity

Discontinued — last reported Q4 '20

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
1.4×+1.1×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
0.2×+0.1×
ALN
Alnylam PharmaceuticalsALNY
0.2×-0.4×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
0.1×0.0×
Roivant Sciences logo
Roivant SciencesROIV
0.0×

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Current ratio1.5×-3.0×

Where this comes from

Calculated from BridgeBio Pharma’s reported figures.

Based on the most recent quarter.

The official record: BridgeBio Pharma’s 10-K, filed February 23, 2023, on SEC EDGAR. View the filing →

Questions, answered.

What does debt-to-equity mean?
How much debt the company carries for every dollar of shareholder equity.
How do you interpret debt-to-equity?
Lower is generally safer, but moderate leverage can boost returns. Read in the context of cash-flow stability — a utility tolerates more debt than a cyclical. Negative equity makes the ratio meaningless and it is suppressed there.
How does debt-to-equity compare across companies?
Comparable within an industry; capital structures differ sharply across sectors. Not meaningful for banks.